Search
BioVie Inc
BIVIAdd to Watchlist
1.950USD
-0.230-10.55%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.71MMarket Cap
LossP/E TTM
More Details of BioVie Inc Company
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
BioVie Inc Info
Ticker SymbolBIVI
Company nameBioVie Inc
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 14
Address680 W Nye Lane
CityCARSON CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code89703
Phone17758883162
Websitehttps://www.bioviepharma.com/
Ticker SymbolBIVI
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)
Company Executives of BioVie Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
1.19K
+8.38%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
941.00
+10.63%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
+0.14%
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Mr. Sigmund (Sig) Rogich
Mr. Sigmund (Sig) Rogich
Independent Director
Independent Director
--
--
Mr. Viet Cuong Do
Mr. Viet Cuong Do
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Amy S. Chappell, M.D.
Dr. Amy S. Chappell, M.D.
Independent Director
Independent Director
--
--
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Independent Director
Independent Director
--
--
Mr. Bruce Mackle
Mr. Bruce Mackle
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
1.19K
+8.38%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
941.00
+10.63%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
+0.14%
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Mr. Sigmund (Sig) Rogich
Mr. Sigmund (Sig) Rogich
Independent Director
Independent Director
--
--
Mr. Viet Cuong Do
Mr. Viet Cuong Do
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of BioVie Inc?
The top five shareholders of BioVie Inc are: Dr. Joseph M. Palumbo, M.D.
How many institutions hold shares of BioVie Inc (BIVI)?
As of 2026Q1, 125 institutions hold shares of BioVie Inc, with a combined market value of approximately 1.18M, accounting for 15.63% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -357412.00.